Autism-focused medical device developer NeuroSpectrum Insights sets terms for $17 million IPO
IPO Overview
NeuroSpectrum Insights, which is developing a medical device for diagnosing neurological and neurodevelopmental disorders, announced terms for its IPO on Tuesday.
The Bedminster, NJ-based company plans to raise $17 million by offering 3.8 million shares at a price range of $4 to $5.
NeuroSpectrum Insights is a medical device company developing computerized analysis technology that enhances clinicians’ capabilities in diagnosing neurological and neurodevelopmental disorders. The company’s first product, GyriCalc, is a proprietary, patented software solution specifically designed to assist in the diagnosis of autism by identifying early structural markers of neurodevelopmental differences through the automated analysis of MRI images. NeuroSpectrum Insights has not generated any revenues to date.
NeuroSpectrum Insights was founded in 2016. It plans to list on the NYSE under the symbol NSIH. Network 1 Financial Securities is the sole bookrunner on the deal.
About the Company
We are a medical device company preparing to commercialize breakthrough computerized analysis technology that enhances clinicians’ capabilities in diagnosing neurological and neurodevelopmental disorders. NSI’s first product, GyriCalc is a proprietary, patented software solution specifically designed to assist in the diagnosis of autism by identifying early structural markers of neurodevelopmental differences through the automated analysis of MRI images. NSI’s initial market focus will be the United States and Canada. In the U.S., we filed for marketing clearance with the FDA in early March 2025 and anticipate receiving approval during 2025. In Canada, where no regulatory approval is required, we recognize the political nature of the healthcare industry and will prioritize strategic discussions with influential government departments and non-profit organizations to ensure a successful market entry. Currently, NSI does not generate any revenue. Our primary focus is on successfully launching GyriCalc for autism and establishing a foothold in the U.S. and Canadian markets.